LOW DOSE LIVER IRRADIATION WITH HEPATIC ARTERIAL CHEMOTHERAPY FOR CANCER

低剂量肝脏照射联合肝动脉化疗治疗癌症

• 批准号: 6263655
• 负责人: CORNELIUS J MCGINN
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263655
• 关键词: clinical research; clinical trial phase I; combination therapy; floxuridine; human subject; human therapy evaluation; liver neoplasms; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; radiation therapy dosage; whole body irradiation dosage

Although radiation has proven efficacy in the treatment of patients with intrahepatic cancers, its usefulness in the treatment of the whole liver is limited by the low dose that can be tolerated when radiation is delivered in conventional fraction sizes. In this phase I study, low dose per fraction irradiation (1 Gy) will be used inorder to determine if a higher total dose can be safely delivered to the whole liver. Radiation will be delivered concurrent with hepatic arterial (HA) floxuridine (FUdR).

虽然放射治疗已被证明在治疗肝内癌患者中有效，但其在治疗整个肝脏中的有效性受到低剂量的限制，当以常规剂量递送放射时，低剂量是可以耐受的。 在这项I期研究中，将使用低剂量/分次照射（1戈伊），以确定是否可以安全地将更高的总剂量输送到整个肝脏。 放射将与肝动脉（HA）尿苷（FUdR）同时输送。